We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Rapid Malaria Tests Assessed After Artemisinin Therapy

By LabMedica International staff writers
Posted on 21 Oct 2013
Plasmodium falciparum-specific rapid diagnostic tests (RDTs) have been used to detect recurrent infections after artemisinin-based combination therapy (ACT).

High specificity of RDTs to distinguish an active P. More...
falciparum infection from residual antigens from a previous infection is crucial in endemic areas where residents are repeatedly exposed to malaria.

Scientists at Karolinska Institute (Stockholm, Sweden) studied 53 Tanzanian children less than five years of age with uncomplicated P. falciparum malaria infections. The children were followed up on nine occasions after initiation of artemether-lumefantrine treatment. At each visit capillary blood samples was collected for the histidine-rich protein 2 (HRP2 and lactate dehydrogenase (LDH)-based RDTs, Giemsa and acridine orange-stained blood smears for microscopy and real-time polymerase chain reaction (PCR).

The two RDTs used were the ParaHITf (Span Diagnostics Ltd.; Surat, India) that detects P. falciparum-specific HRP2 antigen and the CareStart Malaria assay (AccessBio; Somerset, NJ, USA) that detects P. falciparum-specific LDH antigen and were performed and interpreted on site. PCR genotyping was performed to distinguish reinfections from recrudescence. Assessment of clearance times and detection of recurrent P. falciparum infections were done for all diagnostic methods.

The median clearance times were 28 (range 7 to greater than 42) and 7 (2 to 14) days for HRP2 and LDH-based RDTs, 2 (1 to 7) and 2 (1 to 14) days for Giemsa and acridine orange-stained blood smear and 2 (1 to 28) days for real-time PCR. RDT specificity against Giemsa-stained blood smear microscopy was 21% for HRP2 on day 14, reaching 87% on day 42, and equal to or greater than 96% from day 14 to 42 for LDH. There was no significant correlation between parasite density at enrolment and duration of HRP2 positivity. Recurrent malaria infections occurred in 10 children and the HRP2 did not detect eight recurrent infections and LDH-based RDTs did not detect two.

The authors concluded that the LDH-based RDT was superior to HRP2-based for monitoring of treatment outcome and detection of recurrent infections after ACT in this moderately high transmission setting. The results may have implications for the choice of RDT devices in similar transmission settings for improved malaria case management. The study was published on October 1, 2013, in the Malaria Journal.

Related Links:
Karolinska Institute
Span Diagnostics Ltd.
Access Bio Inc.



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.